Abstract
Type 2 Diabetes Mellitus (T2DM) is the most challenging health issue of the
21st century; it results from a complex interaction between multiple gene and
environmental factors. TCF7L2 encodes a transcription factor that is involved in the
Wnt signaling pathway that regulates gene expression of pro-glucagon. Effective
treatment is needed to properly manage T2DM patients. Currently, 5 major classes of
oral pharmacological agents are available for the treatment of T2DM, like metformin,
sulfonylureas, meglitinides, thiazolidinedione, and alpha-glucosidase inhibitors
Keywords: TCF7L2, Wnt signaling, Pharmacological agent, Type 2 diabetes mellitus
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Aging Science
Anti-Infective Agents
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents